Ketamine Therapy for Depression: How It Works, Types, Cost, and What to Expect

Ketamine represents a fundamentally different approach to treating depression. Traditional antidepressants (SSRIs, SNRIs) modulate serotonin and norepinephrine and take 4-6 weeks to work. Ketamine acts on the glutamate system — the brain's primary excitatory neurotransmitter — and can produce antidepressant effects within hours. For the estimated 30% of depression patients who don't respond to standard treatments, ketamine has been transformative. It's the first truly novel mechanism of antidepressant action since the discovery of SSRIs in the 1980s.

Ketamine is an NMDA glutamate receptor antagonist, but its antidepressant effect involves a complex cascade beyond simple receptor blockade:

1. NMDA blockade on GABAergic interneurons disinhibits glutamate release
2. Glutamate surge activates AMPA receptors
3. AMPA activation triggers BDNF (brain-derived neurotrophic factor) release
4. BDNF activates mTOR, stimulating synaptogenesis — the formation of new synaptic connections
5. New synapses in the prefrontal cortex restore connectivity lost during depression

This synaptogenesis hypothesis explains both the rapid onset (new connections form within hours) and the transience of effects (connections may be pruned without ongoing stimulation). Depression is increasingly understood as a disorder of synaptic loss and disconnection, particularly in the prefrontal cortex, and ketamine directly reverses this.

IV ketamine (off-label): Racemic ketamine administered intravenously at sub-anesthetic doses (typically 0.5 mg/kg over 40 minutes). Available at hundreds of private clinics. Standard protocol: 6 infusions over 2-3 weeks, then maintenance infusions as needed (weekly to monthly). Insurance rarely covers it. Cost: $400-800 per infusion.

Esketamine (Spravato) (FDA-approved): The S-enantiomer of ketamine, administered as a nasal spray in certified healthcare facilities under observation. FDA-approved for treatment-resistant depression and MDD with suicidal ideation. Administered twice weekly for 4 weeks, then weekly or biweekly. Must remain in clinic for 2 hours post-dose. Insurance often covers it with prior authorization. Cost with insurance: varies; without: ~$600-900 per session.

Key differences: IV ketamine allows precise dosing and may be more effective per session. Esketamine has FDA approval, a REMS safety program, and better insurance coverage. Both require ongoing treatment for sustained benefit.

During infusion/spray: Patients typically experience dissociation (feeling disconnected from body), perceptual distortions (visual and auditory changes), dizziness, nausea, and elevated blood pressure. Many describe the experience as dreamlike, floating, or surreal. These acute effects resolve within 1-2 hours. Some patients find the dissociation pleasant; others find it uncomfortable. Anxiety before the first session is common and normal.

After treatment: Many patients notice mood improvement within hours to days. The 'lightening' of depression is often described as sudden and distinct — 'like a weight being lifted.' Cognitive flexibility improves. Suicidal thoughts often decrease rapidly (faster than any other treatment). However, these effects typically wane over 1-3 weeks, necessitating maintenance treatments.

Ketamine therapy is generally considered for:

• Treatment-resistant depression (failed 2+ adequate antidepressant trials)
• MDD with acute suicidal ideation (when rapid response is critical)
• Severe depression requiring faster onset than traditional antidepressants
• Depression that partially responds to antidepressants but needs augmentation

It is not appropriate for: active psychosis, uncontrolled hypertension, history of ketamine abuse, unstable aneurysm or AV malformation, pregnancy, or active substance use disorder involving ketamine or PCP.

Transience: The biggest limitation. Effects typically last 1-3 weeks per treatment, requiring ongoing maintenance. Long-term protocols are not well standardized. Abuse potential: Ketamine is a Schedule III controlled substance. Chronic recreational use causes bladder damage (ketamine cystitis) and cognitive impairment. Clinical doses are much lower than recreational doses, and clinic-administered treatment controls access. Dissociation: Not dangerous but can be distressing. Blood pressure: Transiently elevated during treatment; monitor closely. Unknown long-term effects: The safety of repeated low-dose ketamine over years has not been studied in controlled trials. Cost: Even with insurance, maintenance treatment is expensive.